期刊文献+

Prognostic angiogenic markers(endoglin, VEGF, CD31) and tumor cell proliferation(Ki67) for gastrointestinal stromal tumors 被引量:17

Prognostic angiogenic markers(endoglin, VEGF, CD31) and tumor cell proliferation(Ki67) for gastrointestinal stromal tumors
在线阅读 下载PDF
导出
摘要 AIM: To evaluate the correlation between the immunoexpression of angiogenic markers [CD31, CD105 and vascular endothelial growth factor(VEGF)], proliferative index(Ki67), and prognosis of patients with gastrointestinal stromal tumors(GIST).METHODS: This is a retrospective study of 54 GIST cases. Medical records were searched to obtain the GIST patients' demographic and clinical data, and paraffin-embedded blocks of tumor samples were retrieved from the hospital archives to conduct a new immunohistochemical evaluation. The tumor samples of GIST patients were subject to immunohistochemical evaluation for endoglin(CD105), CD31, VEGF, and Ki67 expression. The CD105 and CD31 intratumoral microvascular density(IMVD) was measured using automated analysis. We determined the correlation between the immunoexpression of CD105, CD31, VEGF,Ki67 and prognosis. In addition, we conducted a cutoff analysis using the receiver-operating characteristic curve. VEGF positivity was classified as either null/weak or strong. Ki67 was evaluated using a cutoff of 5%positive cells. The prognosis was classified as good(patient alive without recurrence) or poor(patient with recurrence/death).RESULTS: The distribution of tumor sites among the54 analyzed samples was as follows: 27(50%) in the stomach, 20(37.1%) in the small intestine, 6(11.1%)in the colon, and 1(1.8%) in the esophagus. The size of the tumors ranged from 2 to 33 cm(median: 8cm); in 12 cases(22.2%), the tumor was below 5 cm at the largest diameter, but in 42 cases(77.7%), the tumor was larger than 5 cm. The means of CD105 and CD31 were significantly higher in the group with poor prognosis(P < 0.001). The cut-off values of CD105(>1.2%) and CD31(> 2.5%) in the receiver-operating characteristic curve were related to a poorer prognosis.Cases with a better prognosis showed significantly null/weak staining for VEGF(P < 0.001). Ki-67 expression of≥ 5% was strongly correlated with a worse prognosis(P< 0.001). In the multivariate analysis, CD105 was the variable that most strongly correlated with prognosis.CONCLUSION: The IMVD cutoff values for the angiogenic markers CD105 and CD31, may be prognostic factors for GIST, in addition to VEGF and Ki67. AIM: To evaluate the correlation between the immunoexpression of angiogenic markers [CD31, CD105 and vascular endothelial growth factor(VEGF)], proliferative index(Ki67), and prognosis of patients with gastrointestinal stromal tumors(GIST).METHODS: This is a retrospective study of 54 GIST cases. Medical records were searched to obtain the GIST patients' demographic and clinical data, and paraffin-embedded blocks of tumor samples were retrieved from the hospital archives to conduct a new immunohistochemical evaluation. The tumor samples of GIST patients were subject to immunohistochemical evaluation for endoglin(CD105), CD31, VEGF, and Ki67 expression. The CD105 and CD31 intratumoral microvascular density(IMVD) was measured using automated analysis. We determined the correlation between the immunoexpression of CD105, CD31, VEGF,Ki67 and prognosis. In addition, we conducted a cutoff analysis using the receiver-operating characteristic curve. VEGF positivity was classified as either null/weak or strong. Ki67 was evaluated using a cutoff of 5%positive cells. The prognosis was classified as good(patient alive without recurrence) or poor(patient with recurrence/death).RESULTS: The distribution of tumor sites among the54 analyzed samples was as follows: 27(50%) in the stomach, 20(37.1%) in the small intestine, 6(11.1%)in the colon, and 1(1.8%) in the esophagus. The size of the tumors ranged from 2 to 33 cm(median: 8cm); in 12 cases(22.2%), the tumor was below 5 cm at the largest diameter, but in 42 cases(77.7%), the tumor was larger than 5 cm. The means of CD105 and CD31 were significantly higher in the group with poor prognosis(P < 0.001). The cut-off values of CD105(>1.2%) and CD31(> 2.5%) in the receiver-operating characteristic curve were related to a poorer prognosis.Cases with a better prognosis showed significantly null/weak staining for VEGF(P < 0.001). Ki-67 expression of≥ 5% was strongly correlated with a worse prognosis(P< 0.001). In the multivariate analysis, CD105 was the variable that most strongly correlated with prognosis.CONCLUSION: The IMVD cutoff values for the angiogenic markers CD105 and CD31, may be prognostic factors for GIST, in addition to VEGF and Ki67.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第22期6924-6930,共7页 世界胃肠病学杂志(英文版)
关键词 Angiogenesis Immunohistochemistry CD105 CD31 GASTROINTESTINAL STROMAL tumors Vascularendothelial growth factor Ki-67 Angiogenesis Immunohistochemistry,CD105 CD31 Gastrointestinal stromal tumors Vascular endothelial growth factor Ki-67
  • 相关文献

参考文献44

  • 1Miettinen M, Lasota J. Histopathology of gastrointestinal stromaltumor. J Surg Oncol 2011; 104: 865-873 [PMID: 22069171 DOI:10.1002/jso.21945].
  • 2Rubin BP. Gastrointestinal stromal tumours: an update.Histopathology 2006; 48: 83-96 [PMID: 16359540].
  • 3Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL,Zewe JP, Wozniak A, Mehalek KR, Korzeniewski N, SeneviratneDS, Sch-ffski P, Debiec-Rychter M, DeCaprio JA, Duensing A.The DREAM complex mediates GIST cell quiescence and is anovel therapeutic target to enhance imatinib-induced apoptosis.Cancer Res 2013; 73: 5120-5129 [PMID: 23786773 DOI:10.1158/0008-5472.CAN-13-0579].
  • 4Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, LongleyBJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B,Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors:A consensus approach. Hum Pathol 2002; 33: 459-465 [PMID:12094370].
  • 5Miettinen M, Lasota J. Gastrointestinal stromal tumors: reviewon morphology, molecular pathology, prognosis, and differentialdiagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478 [PMID:17090188].
  • 6Joensuu H. Predicting recurrence-free survival after surgery forGIST. Lancet Oncol 2009; 10: 1025 [PMID: 19793677 DOI:10.1016/S1470-2045(09)70267-0].
  • 7Huang H, Liu YX, Zhan ZL, Liang H, Wang P, Ren XB. Differentsites and prognoses of gastrointestinal stromal tumors of thestomach: report of 187 cases. World J Surg 2010; 34: 1523-1533[PMID: 20145924 DOI: 10.1007/s00268-010-0463-y].
  • 8Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, PaulPG, Ooi BS, Chung YF, Wong WK. Which is the optimal riskstratification system for surgically treated localized primaryGIST- Comparison of three contemporary prognostic criteria in171 tumors and a proposal for a modified Armed Forces Instituteof Pathology risk criteria. Ann Surg Oncol 2008; 15: 2153-2163[PMID: 18546045 DOI: 10.1245/s10434-008-9969-z].
  • 9Wong NA. Gastrointestinal stromal tumours-an update forhistopathologists. Histopathology 2011; 59: 807-821 [PMID:21668468 DOI: 10.1111/j.1365-2559.2011.03812.x].
  • 10Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathologyand prognosis at different sites. Semin Diagn Pathol 2006; 23:70-83 [PMID: 17193820].

同被引文献196

  • 1Yoko Matsuda,Masahito Hagio,Toshiyuki Ishiwata.Nestin:A novel angiogenesis marker and possible target for tumor angiogenesis[J].World Journal of Gastroenterology,2013,19(1):42-48. 被引量:16
  • 2Wei-Jun Cao,Hai-Lu Wu,Bang-Shun He,Yu-Shu Zhang,Zhen-Yu Zhang.Analysis of long non-coding RNA expression profiles in gastric cancer[J].World Journal of Gastroenterology,2013,19(23):3658-3664. 被引量:33
  • 3梁建芳,郑绘霞,李宁,程彩霞,肖虹,王宏坤.胃肠道间质瘤中P16基因甲基化和P16蛋白表达的临床意义[J].中华胃肠外科杂志,2007,10(4):372-375. 被引量:8
  • 4匡志鹏,谢裕安,杨帆,梁安民,罗小玲,吴继宁.C57BL/6J小鼠肝癌动物模型的建立[J].中国普通外科杂志,2007,16(7):657-660. 被引量:38
  • 5Katrin Panzitt,Marisa M.O. Tschernatsch,Christian Guelly,Tarek Moustafa,Martin Stradner,Heimo M. Strohmaier,Charles R. Buck,Helmut Denk,Renée Schroeder,Michael Trauner,Kurt Zatloukal.Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA[J]. Gastroenterology . 2007 (1)
  • 6Ramiro Garzon,George A. Calin,Carlo M. Croce.MicroRNAs in Cancer[J]. Annual Review of Medicine . 2009
  • 7Ji-Seon Park,Sun Young Yoon,Jeong-Min Kim,Young-Il Yeom,Yong Sung Kim,Nam-Soon Kim.Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray[J].Cancer Letters.2004(1)
  • 8Atsushi Nashimoto,Kohei Akazawa,Yoh Isobe,Isao Miyashiro,Hitoshi Katai,Yasuhiro Kodera,Shunichi Tsujitani,Yasuyuki Seto,Hiroshi Furukawa,Ichiro Oda,Hiroyuki Ono,Satoshi Tanabe,Michio Kaminishi.Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry[J].Gastric Cancer.2013(1)
  • 9Feng Yang,Xuchao Xue,Jianwei Bi,Luming Zheng,Kangkang Zhi,Yan Gu,Guoen Fang.Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma[J].Journal of Cancer Research and Clinical Oncology.2013(3)
  • 10Hao Huang,Yong Han,Jing Gao,Junnan Feng,Lei Zhu,Like Qu,Lin Shen,Chengchao Shou.High level of serum AMBP is associated with poor response to paclitaxel–capecitabine chemotherapy in advanced gastric cancer patients[J].Medical Oncology.2013(4)

引证文献17

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部